Study of MDW Levels Predicting the Development of Sepsis in Hospitalized HIV-infected Patients and Correlation With Prognosis

Sponsor
Shanghai Public Health Clinical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05036928
Collaborator
(none)
450
1
10
45.1

Study Details

Study Description

Brief Summary

Sepsis is a common and critical complication in HIV-infected patients and an important marker of high risk of patient death. The widely used diagnostic criteria for sepsis still have many deficiencies and do not allow for good prediction and timely determination of the onset of sepsis. In HIV-infected patients, abnormal activation of monocyte-macrophage is also a key mechanism in the development of their sepsis. Monocyte distribution width (MDW) is a marker of the degree of peripheral blood monocyte activation and has been recommended abroad for the early diagnosis of adult sepsis patients in emergency departments. However, in China, MDW has not been applied to the clinic yet, and the related studies are almost blank. Therefore, it is worthwhile to analyze the monocyte activation status of HIV-infected patients by MDW assay and thus predict the occurrence of sepsis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Monocyte distribution width (MDW)

Detailed Description

This is a prospective observational study, and investigators intend to collect HIV-infected patients in our hospital within 1 year from the conduct of this study and hospitalized, after informed consent, for inclusion in the study. Investigators will collect clinical data, basic laboratory indicators, and test MDW levels of the patients and follow the patients until discharge or death.

Study Design

Study Type:
Observational
Anticipated Enrollment :
450 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study of MDW Levels Predicting the Development of Sepsis in Hospitalized HIV-infected Patients and Correlation With Prognosis
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
HIV infection group

Diagnostic Test: Monocyte distribution width (MDW)
All enrolled patients will receive test with MDW.

Outcome Measures

Primary Outcome Measures

  1. Number of participants with sepsis of admission [within 28 days]

    Using Sepsis 3.0 as the diagnostic criteria, the sensitivity and specificity of using MDW to diagnose sepsis in HIV-infected patients.

  2. Number of deaths of enrolled patients [within 28 days]

    In HIV infection with sepsis, whether higher MDW score is related to poor prognosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Positive ELISA test results for HIV-1 antibodies;

  • Hospitalized patients; Voluntarily signing the patient's informed consent and being able to promise to be followed up;

  • No plans to move away from the current trial site during the course of the trial.

Exclusion Criteria:
  • Western Blot and/or HIV RNA assay confirmed as HIV negative;

  • Women who are pregnant or breastfeeding;

  • Current drug users;

  • Persons with a history of alcohol abuse that cannot be terminated;

  • Persons of non-Chinese nationality;

  • Other patients who, in the judgment of the investigator, are deemed unsuitable for participation in this trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shanghai Public Health Clinical Center Shanghai Shanghai China 201508

Sponsors and Collaborators

  • Shanghai Public Health Clinical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jun Chen, MD, Deputy Director of Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center
ClinicalTrials.gov Identifier:
NCT05036928
Other Study ID Numbers:
  • HIV-MDW
First Posted:
Sep 8, 2021
Last Update Posted:
Nov 30, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 30, 2021